A look ahead: future directions of SSR-directed imaging and therapy in meningioma

AbstractBackgroundMeningiomas, which are the most common of CNS tumours in adults, show a high expression of the somatostatin receptor subtype 2 (SSR). Visualization of these receptors with specific PET ligands augments contrast-enhanced MRI and CT of the brain in resolving several clinical issues related to differential diagnosis, evaluation of meningioma extent, and therapy planning or follow-up. Moreover, SSR-directed radioligands labeled with beta-emitters serve for radiopeptide therapy (RPT) in patients with recurrent or refractory meningioma. In the light of recent developments in radiochemistry, neuropathology/molecular genetics, and emerging systemic treatments, we present our perspective on future directions of SSR-directed imaging and therapy in meningioma.MethodsWe conducted a search in the PubMed literature database until June 2019 using the terms “meningioma”, “PET”, “somatostatin receptor”, “SS(T)R”, “DOTATATE”, “DOTATOC”, “radiopeptide therapy”, “imaging”, “therapy”, “classification” alone and in combination, compiled with relevant literature from the authors’ own files.Results/conclusionOur review identifies important emerging applications of SSR-directed imaging and therapy in patients with meningioma. We summarize the state of development novel SSR-directed radio-ligands, meningioma classifications and systemic treatment options.

Source: Clinical and Translational Imaging - July 7, 2019 Category: Radiology Source Type: research